论文部分内容阅读
目的研究乳腺癌p 5 3,ki-6 7和bcl-2基因蛋白表达与新辅助化疗临床效果的关系,以寻找指导治疗、判断预后的生物学指标。方法采用免疫组化SABC法测定1 1 8例可手术的乳腺癌标本的p 5 3,ki-6 7和bcl-2的蛋白表达,并分析其与新辅助化疗疗效的关系。结果术前辅助化疗有效率为68.6%。p 5 3表达阳性,化疗效果差(P<0.0 5);而ki-6 7阳性表达者有效率明显高于ki-6 7不表达者(P<0.0 5);bcl-2表达与疗效无明显关系。p 5 3蛋白阳性表达者bcl-2表达下降。p 5 3与ki-6 7蛋白表达有明显关系。结论p 5 3和ki-6 7蛋白表达可作为指导新辅助化疗及预后判断的分子生物学指标。
Objective To investigate the relationship between the expression of p53, ki-67 and bcl-2 protein in breast cancer and the clinical effect of neoadjuvant chemotherapy in order to find out the biological indicators for guiding treatment and prognosis. Methods Immunohistochemical SABC method was used to determine the protein expressions of p 5 3, ki-6 7 and bcl-2 in 11 cases of operable breast cancer specimens and to analyze their relationship with the efficacy of neoadjuvant chemotherapy. Results The effective rate of preoperative adjuvant chemotherapy was 68.6%. (P <0.05). However, the effective rate of ki-6 7 positive expression was significantly higher than that of ki-6 7 non-expression (P <0.0 5). The expression and curative effect of bcl-2 Obvious relationship. The expression of bcl-2 in p 5 3 protein positive cells decreased. There is a clear relationship between p 5 3 and ki-6 7 protein expression. Conclusion The expressions of p 5 3 and ki-6 7 may be used as molecular biological indicators to guide neoadjuvant chemotherapy and prognosis.